

MORTALITY OF HIV/HBV COINFECTED PATIENTS ON ART IN URBAN AND RURAL SOUTHERN AFRICA

[Jonas Hector](#)¹, [Michael J Vinikoor](#)^{2,3}, [Kalo Musukuma](#)², [Roma Chilengi](#)², [Laura Jefferys](#)¹, [Michael Hobbins](#)¹, [Mary-Ann Davies](#)⁴, [Matthias Egger](#)^{4,5}, [Gilles Wandeler](#)^{5,6}
for leDEA-Southern Africa

¹ SolidarMed, Arcuabe, Mozambique, ² Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, ³ Department of Medicine at University of Alabama, Birmingham, United States of America, ⁴ School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa ⁵ Institute of Social & Preventive Medicine (ISPM), University of Bern, Switzerland; ⁶ Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland

Background

- Chronic hepatitis B virus (HBV) infection affects approximately 10% of HIV-positive people in sub-Saharan Africa (SSA)¹ and is an important risk factor for liver-related events and death.
- Due to high rates of losses to follow-up (LTFU) in African HIV clinics², precise mortality estimates among cohorts of patients on antiretroviral therapy (ART) are scarce.

Objectives

- To compare one-year mortality of HIV/HBV-coinfected patients on tenofovir (TDF)-containing ART between rural and urban primary care clinics in southern Africa after the systematic tracing of patients LTFU.
- To assess risk factors for all cause mortality.

Methods

Study Population and Inclusion Criteria

- We included HIV/HBV coinfected adults (>16 years) initiating TDF-containing ART at two urban clinics in Lusaka, Zambia, and three rural clinics in northern Mozambique between May 2013 and July 2015.

Procedures

- HBV infection was assessed using HBsAg rapid tests (Determine®).
- Quantitative real-time PCR for HBV viral load was performed using the COBAS AmpliPrep/TaqMan System and HBV sequencing according to an in-house protocol³.
- Medication possession ratio (MPR, calculated as days of ART possession/ 365 days*100) was used as a proxy for treatment adherence³.
- All patients LTFU (>3 months without a clinical visit) were traced by phone and home visits for ascertainment of vital status.

Statistical analyses

- Baseline characteristics were compared between treatment settings using Fisher's exact test and Wilcoxon rank sum tests.
- Mortality and associated risk factors were assessed using multivariable Cox proportional hazards regression.

Results

Table 1. Demographic and clinical characteristics, by country

	Rural Mozambique N=78	Urban Zambia N=184	p-value
Female (%)	47 (60.3)	76 (41.3)	<0.001
Median age in years (IQR)	30 (25-39)	34 (28-39)	0.14
Median BMI (IQR)	19.5 (18.2-21.6)	20.2 (18.6-23.1)	0.11
Median CD4 cells/μl (IQR)	232 (122-539)	208 (97-351)	0.03
WHO stage 3 or 4 (%)	33 (42.3)	74 (41.6)	0.50
Median ALT (IQR)	31 (19-59)	23 (15-40)	0.04
Moderate to severe anaemia (%)	34 (56.7)	43 (25.3)	<0.001
HBV genotype (%)			<0.001
A1	68 ()	41 ()	
E	14 ()	50 ()	
Other			
HBV viral load >20,000 IU/ml (%)	38 (52.8)	77 (45)	0.17

- 263 HIV/HBV-coinfected patients were included. Patients in Mozambique were more likely to be female, to have moderate or severe anaemia (<11g/dl for men and < 10g/dl for women), elevated ALT levels and higher CD4 cell counts (Table 1).
- At 1 year, after the systematic tracing of patients LTFU, vital status was unknown in only one patient (1.3%) in Mozambique and 7 patients (3.8%) in Zambia.
- The MPR in patients with one year follow up was 69% (95% CI 20.3-89.3) in Mozambique and 97% (95% CI 97.8-100) in Zambia (p<0.01).

Figure 1. Survival of HIV/Hepatitis B-coinfected patients on ART, by country




Table 2. Risk factors for mortality

	HR (95% CI)	P-value	aHR (95% CI)	p-value
Origin (ref. Moz)	0.49 (0.23-1.04)	0.06	1.56 (0.51-4.81)	0.43
Male sex	3.36 (1.36-8.35)	0.01	4.00 (1.07-15.01)	0.04
Moderate/severe anaemia	6.50 (2.58-16.36)	<0.001	8.64 (2.35-31.78)	0.001
CD4<200/μl	2.22 (0.94-5.23)	0.07	0.84 (0.29-2.49)	0.76
Age in years	1.04 (1.00-1.07)	0.05	1.01 (0.97-1.07)	0.52
BMI	0.75 (0.64-0.88)	<0.001	0.72 (0.57-0.91)	0.01
HBV Viral load > 20,000 IU/ml	0.96 (0.42-2.23)	0.93	-	-
ALT	1.00 (0.98-1.01)	0.61	-	-
WHO stage 3 or 4	2.06 (0.96-4.45)	0.06	0.82 (0.30-2.31)	0.72

HR: hazard ratios, aHR: adjusted hazard ratios, CI: confidence interval, BMI: body mass index, ALT: alanine aminotransferase

- One-year mortality was 16 % in Mozambique and 8% in Zambia (p=0.06) (Fig. 1).
- In adjusted analyses, low BMI, moderate/severe anaemia and male sex were independent risk factors for mortality (Table 2).
- HBV viral load did not have an impact on 1-year mortality among HIV/HBV-coinfected individuals on TDF-containing ART.

Conclusions

- Early mortality of HIV/HBV-coinfected individuals on ART is very high in SSA, especially in rural settings, where access to care and treatment adherence may be reduced.
- Tracing of patients LTFU is needed if precise mortality estimates are to be obtained in rural SSA clinics.

References

- Wandeler G et al. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. PLoS One. 2016 Mar 31;11(3):e0152043
 - Wandeler G et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):e9-16
 - Vinikoor M et al. Late refills during the first year of antiretroviral therapy predict mortality and program failure among HIV-infected adults in urban Zambia. AIDS Res Hum Retroviruses. 2014 Jan;30(1):74-7
- Funding sources**
This study was supported by the National Institute of Allergy and Infectious Diseases (Grant number 5U01-AI069924-05) and Fogarty International Center (Grant number 1K01 TW009988) of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. GW was supported by an Ambizione-PROSPER fellowship (P200P3_154730) from the Swiss National Science Foundation.